Luveltamab Tazevibulin is a monoclonal antibody conjugated commercialized by Sutro Biopharma, with a leading Phase III program in Peritoneal Cancer. According to Globaldata, it is involved in 6 clinical trials, of which 4 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Luveltamab Tazevibulin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Luveltamab Tazevibulin is expected to reach an annual total of $163 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Luveltamab Tazevibulin Overview
STRO-002 is under development for the treatment of solid tumors, relapsed/refractory cancers like epithelial ovarian cancer, endometrial carcinoma, fallopian tube cancer, peritoneal cancer, non-small cell lung cancer, triple negative breast cancer, adenocarcinoma and relapsed/refractory rare pediatric acute myeloid leukemia (AML). It is administered through intravenous route. It is developed based on Xpress CF plus platform technology. The drug candidate is a potent and Sutro proprietary hemia-sterlin derivative warhead. It is a monoclonal antibody conjugate that acts by targeting folate receptor alpha (FolR alpha).
Sutro Biopharma Overview
Sutro Biopharma is a clinical-stage oncology company. It develops next-generation cancer therapeutics which include antibody-drug conjugates (ADCs), bispecific antibodies, cytokine-based immuno-oncology therapies and vaccines through the XpressCF and XpressCF+ platforms. The company’s pipeline products include STRO-001 to treat B-cell malignancies; STRO-002, luvelta treats ovarian cancer, endometrial cancer, adenocarcinoma, non-small cell lung cancer, GLlS2 pediatric acute myeloid leukemia; STRO-003 treats solid tumors, hematological cancers, STRO-004 treat solid tumors, VAX-24, MK-1484 treats invasive pneumococcal disease and metastatic solid tumors. It works in collaboration with Merck & Co., Inc and Astellas Pharma Inc., among others. Sutro Biopharma is headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$67.8 million for the fiscal year ended December 2022 (FY2022), an increase of 9.5% over FY2021. The operating loss of the company was US$128.9 million in FY2022, compared to an operating loss of US$98.5 million in FY2021. The net loss of the company was US$119.2 million in FY2022, compared to a net loss of US$105.5 million in FY2021. The company reported revenues of US$16.9 million for the third quarter ended September 2023, an increase of 62.5% over the previous quarter.
For a complete picture of Luveltamab Tazevibulin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.